Imugene share price seesaws on ‘clarification announcement’

What did Imugene update the ASX with?

| More on:
Two researchers discussing results of a study with each other.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Imugene shares backtrack 1.58% to 18.7 cents 
  • The company provided further clarification regarding the terminated supply agreement for HER-Vaxx by MSD 
  • Management advised that this will not affect the material cost to the clinical trial 

The Imugene Limited (ASX: IMU) share price is moving in circles during Tuesday afternoon following an update from the company.

At the time of writing, the immuno-oncology company’s shares are down 1.58% to 18.7 cents.

It’s worth noting that Imugene shares have now lost more than 25% in the past week.

Imugene provides update on terminated supply contract

Investors are continuing to sell off Imugene shares despite the company’s clarification announcement made to the ASX today.

According to its release, Imugene advised that the terminated supply agreement by MSD is not a key factors regarding HER-Vaxx. This relates to the technology, clinical trial design, trial data, and the safety of the immunotherapy.

MSD is a tradename of pharmaceutical giant, Merck & Co.

Furthermore, management noted that the study will run as planned with alternate supply arrangements available to the company. This includes direct reimbursement of hospital pharmacies.

Subsequently, Imugene stated that there is no material difference to the cost of the trial as budgeted, or the agreement.

More on HER-Vaxx

HER-Vaxx is a B-cell immunotherapy that has been shown in studies to “stimulate a potent polyclonal antibody response to HER-2/neu, a well-known and validated cancer target.”

The immunotherapy is being developed for the treatment of gastric, breast, ovarian, lung and pancreatic cancers.

The primary objective of the upcoming clinical trial is to determine the safety and efficacy of HER-Vaxx in combination with anti-PD-1 therapy.

PD1-Vaxx advantage is that it induces a unique polyclonal immune response that may increase response rates for therapy.

Imugene share price snapshot

Adding to today’s fall, the Imugene share price is down 8% over the past 12 months.

However, when looking at year to date, its shares have lost half of their value.

Imugene shares reached an all-time high of 62.5 cents in November, before moving on a downhill trend.

Based on valuation metrics, Imugene has a market capitalisation of roughly $1.09 billion.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A businessman presents a company annual report in front of a group seated at a table
Healthcare Shares

Own Immutep shares? Here are 3 takeaways from the company’s investor update

Investors were mute to the update.

Read more »

A health professional wearing a stethoscope and scrubs shrugs with uncertainty.
Healthcare Shares

Has CSL been growing its dividend?

Is the biotech giant still increasing its dividends in a post-COVID world?

Read more »

Man pointing an upward line on a bar graph symbolising a rising share price.
Healthcare Shares

Why is the 4DMedical share price exploding 40% today?

4DMedical signed a three-year, nationwide contract with I-MED Radiology Network.

Read more »

Two medical researchers in white coats collaborate over a computer screen of data in a medical research laboratory
Healthcare Shares

What was the Sonic Healthcare share price when it first listed on the ASX?

Sonic Healthcare has an interesting history...

Read more »

asx share penalty represented by lots of fingers pointing at disgraced businessman Crown royal commission WA
Share Market News

Melbourne man jailed for insider trading of ASX shares

Former executive of a listed company sentenced after selling his stocks while aware of information that the public was not…

Read more »

Happy healthcare workers in a labs
Healthcare Shares

‘Significant milestone’: Why the Imugene share price is soaring 30% today

What's driving the Imugene share price higher today?

Read more »

medical imaging doctor amid images of human brains
Healthcare Shares

The Pro Medicus share price is down 30% in 2022. Is it a buy?

This ASX share has a very high profit margin. But after the volatility, is an opportunity?

Read more »

A scientist in a white coat and glasses puts her arms in the air in a sign of strength and success.
Healthcare Shares

Why this broker is tipping ‘strength in the CSL share price’

A leading broker is feeling positive about the CSL share price...

Read more »